Cystic Fibrosis Patient Testimony on Orkambi

0
(0)

Orkambi is a combination therapy for treatment of cystic fibrosis. The FDA approval for the therapy was announced on July 2nd, 2015.

This is Kate Marshall’s Orkambi testimony before the Open Public Hearing OPH portion of the May 12, 2015 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting in Washington, DC.

Kate is 15 years old and has two copies of the D508 gene, which Orkambi, (the combination of Ivacaftor and Lumacaftor) treats.

Learn more about Orkambi here: http://bit.ly/1jCoQUT

Read all the latest news about Orkambi here: http://bit.ly/1RlPwnh

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *